Scholarlink

Purpose of Review <p>Alzheimer’s disease (AD) is the most common form of dementia, as well as an age-related, progressively worsening neurodegenerative disease. It is primarily characterized by the accumulation of amyloid-beta protein (Aβ) plaques, hyperphosphorylation tau protein, synaptic dysfunction, neuroinflammation, and widespread oxidative stress in the brain. Clinically, AD manifests as severe memory deficit, cognitive decline, psychiatric manifestations, and behavioral abnormalities, significantly impairing an individual’s ability to perform daily activities. At present, the pathogenesis of this devastating and progressive disease remains unknown, making it incurable and irreversible.</p> Recent Findings <p>Recently, a growing body of studies has highlighted the essential role of gut microbiota in human health, disease states and overall well-being. Changes of gut microbiota composition are linked to various diseases, including Clostridium difficile infection (CDI), inflammatory bowel disease (IBD), liver cirrhosis, Parkinson’s Disease (PD) and AD. Moreover, related research indicates that restoring gut microbiota dysbiosis can alleviate disease conditions. In recent years, fecal microbiota transplantation (FMT) has emerged as a novel therapeutic technique to modify the recipient’s gut microbiota, normalize its composition, and confer therapeutic benefits. Some findings indicate that FMT is an effective, safe, and well-tolerated procedure for treating CDI and liver cirrhosis. Although FMT has been used for CDI treatment since the 1980s, its application in treating AD is a relatively recent development. However, questions remain surrounding optimal donor selection, administration methods, dosing strategies, and the long-term effects on AD patients.</p> Summary <p>This review aims to elucidate the connection between gut microbiota and AD, explore the critical role of gut microbiota in AD pathogenesis, and examine the safety, efficacy, and future prospects of FMT in AD treatment based on recent studies. These findings aim to offer fresh perspectives on diagnostic and therapeutic strategies for AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fecal Microbiota Transplantation for Alzheimer’s Disease: a Review of Current Evidence and Future Perspectives

  • 期刊论文

  • 发表日期：

    2025年8月14日

查看全文
  • Zhiyan Zou,
  • Yuan Yin,
  • Bo Liao,
  • Zhou Lu,
  • Mouxiao Su,
  • Xiaoan Li

摘要

Purpose of Review

Alzheimer’s disease (AD) is the most common form of dementia, as well as an age-related, progressively worsening neurodegenerative disease. It is primarily characterized by the accumulation of amyloid-beta protein (Aβ) plaques, hyperphosphorylation tau protein, synaptic dysfunction, neuroinflammation, and widespread oxidative stress in the brain. Clinically, AD manifests as severe memory deficit, cognitive decline, psychiatric manifestations, and behavioral abnormalities, significantly impairing an individual’s ability to perform daily activities. At present, the pathogenesis of this devastating and progressive disease remains unknown, making it incurable and irreversible.

Recent Findings

Recently, a growing body of studies has highlighted the essential role of gut microbiota in human health, disease states and overall well-being. Changes of gut microbiota composition are linked to various diseases, including Clostridium difficile infection (CDI), inflammatory bowel disease (IBD), liver cirrhosis, Parkinson’s Disease (PD) and AD. Moreover, related research indicates that restoring gut microbiota dysbiosis can alleviate disease conditions. In recent years, fecal microbiota transplantation (FMT) has emerged as a novel therapeutic technique to modify the recipient’s gut microbiota, normalize its composition, and confer therapeutic benefits. Some findings indicate that FMT is an effective, safe, and well-tolerated procedure for treating CDI and liver cirrhosis. Although FMT has been used for CDI treatment since the 1980s, its application in treating AD is a relatively recent development. However, questions remain surrounding optimal donor selection, administration methods, dosing strategies, and the long-term effects on AD patients.

Summary

This review aims to elucidate the connection between gut microbiota and AD, explore the critical role of gut microbiota in AD pathogenesis, and examine the safety, efficacy, and future prospects of FMT in AD treatment based on recent studies. These findings aim to offer fresh perspectives on diagnostic and therapeutic strategies for AD.